Literature DB >> 12496684

Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils.

Paolo Tessari1.   

Abstract

PURPOSE OF REVIEW: Liver cirrhosis in the advanced state is characterized by protein wasting, as indicated by the loss of muscle mass, hypoalbuminemia, and an abnormal amino acid profile. The protein wasting condition cirrhosis is associated with a poor prognosis and reduced survival. Poor nutrition, metabolic and hormonal abnormalities, and other disease-associated alterations may all concur to protein wasting. An understanding of the causes and mechanisms leading to protein wasting in cirrhosis may help in the development of nutritional interventions and new therapies. RECENT
FINDINGS: Albumin and muscle protein turnover in cirrhotic patients have been studied in vivo with the aid of isotope dilution techniques or organ catheterization. Albumin synthesis appears to parallel liver function, i.e. the more compromised is the liver, the less is the albumin production rate. Meal-induced albumin synthesis is impaired even in compensated cirrhotic patients. Skeletal muscle protein synthesis is diminished in cirrhosis, and total muscle protein breakdown also appears to be increased, thus explaining the reduced muscle mass. Either hormone or substrate resistance, or newly involved substances (cytokines, insulin-like growth factor 1, leptin) may play a role in the reduced synthesis of both albumin and muscle proteins in liver cirrhosis.
SUMMARY: Abnormalities of both albumin and muscle protein turnover have been demonstrated in liver cirrhotic patients. The possible role of the multiple hormonal and metabolic abnormalities of this disease, as well that of cytokines and other recently discovered substances, need to be investigated further.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496684     DOI: 10.1097/00075197-200301000-00012

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  22 in total

Review 1.  Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Authors:  Thomas W Buford; Stephen D Anton; Andrew R Judge; Emanuele Marzetti; Stephanie E Wohlgemuth; Christy S Carter; Christiaan Leeuwenburgh; Marco Pahor; Todd M Manini
Journal:  Ageing Res Rev       Date:  2010-05-14       Impact factor: 10.895

Review 2.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.

Authors:  Rita Rastogi Kalyani; Mark Corriere; Luigi Ferrucci
Journal:  Lancet Diabetes Endocrinol       Date:  2014-03-06       Impact factor: 32.069

4.  Kinetics of albumin- and alpha-fetoprotein-production during rat liver development.

Authors:  Abderrahim Elmaouhoub; József Dudas; Giuliano Ramadori
Journal:  Histochem Cell Biol       Date:  2007-09-19       Impact factor: 4.304

Review 5.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 6.  Nutrition and exercise in the management of liver cirrhosis.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  Inactivation of deoxynivalenol-contaminated cereal grains with sodium metabisulfite: a review of procedures and toxicological aspects.

Authors:  Sven Dänicke; Susanne Kersten; Hana Valenta; Gerhard Breves
Journal:  Mycotoxin Res       Date:  2012-09-15       Impact factor: 3.833

Review 8.  Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation.

Authors:  Srinivasan Dasarathy
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

9.  Dyspnea and respiratory muscle strength in end-stage liver disease.

Authors:  Georgios Kaltsakas; Efstathios Antoniou; Anastasios F Palamidas; Sofia-Antiopi Gennimata; Panorea Paraskeva; Anastasios Smyrnis; Antonia Koutsoukou; Joseph Milic-Emili; Nickolaos G Koulouris
Journal:  World J Hepatol       Date:  2013-02-27

10.  Sialadenosis in patients with advanced liver disease.

Authors:  James Guggenheimer; John M Close; Bijan Eghtesad
Journal:  Head Neck Pathol       Date:  2009-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.